The definitive first-line treatment for Trichilemmal tumors is, ideally, surgical excision with or without Mohs micrographic technique; however, in view of Her2-positive breast cancer being an aggressive tumor, a multidisciplinary tumor board discussion was held regarding the optimal management strategy. This evidence concerns the gene ERBB2 and breast carcinoma.